-
Lifetech's new generation of abdominal aorta stent graft system was approved for marketing
Time of Update: 2022-01-03
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.
For abdominal aortic aneurysms with more complex anatomical shapes, such as severe angulation and short aneurysm necks, traditional endovascular repair techniques are still Unable to effectively intervene .
-
Saint-Gobain completes equity acquisition of Anhui Huijie New Materials
Time of Update: 2022-01-03
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
62em; font-family:"Arial"; color:black; margin:0in; } </>Huangshan November 26, 2021/PRNewswire/ - Following the successful acquisition of Hangzhou Huijie New Materials Co.
-
Chuangsheng Group announces that its humanized anti-VEGFR-2 monoclonal antibody MSB0254 Phase Ib clinical trial has completed the first patient administration
Time of Update: 2022-01-03
HK), a clinical-stage biopharmaceutical company with full-process integration capabilities for biopharmaceutical discovery, research and development, process development and production, today announced its The humanized anti-VEGFR-2 monoclonal antibody MSB0254 has been administered to the first patient in a phase Ib clinical trial .
-
Deqi Pharmaceutical is included in the MSCI Global Small Cap Index-MSCI China Small Cap Index
Time of Update: 2022-01-03
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
62em; font-family:"Arial"; color:black; margin:0in; } Shanghai and Hong Kong November 26, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
-
Abbots Medical has completed a US$75 million Series A financing, which will bring innovative targeted radiotherapy drugs to cancer patients in the Greater China market
Time of Update: 2022-01-03
62em; font-family:"Arial"; color:black; margin:0in; } Shanghai and San Diego, November 29, 2021/PRNewswire/ - Ablaze Pharmaceuticals ("Ablaze Pharmaceuticals"), a company focused on the development and commercialization of innovative targeted radiotherapy drugs (TRT) targeting tumor targets A clinical-stage pharmaceutical company announced that it has completed a US$75 million Series A financing .
-
A joint study by CUHK and HKU found that "Bifidobacterium adolescentis" can enhance the effectiveness of the new crown vaccine
Time of Update: 2022-01-02
The world's first human body study by CUHK and Hong Kong University found that a bacterium called "Bifidobacterium adolescentis" can improve the effectiveness of the new crown vaccine and enhance its protection .
-
Science Sub-Journal: Make chemotherapy for pancreatic cancer more successful
Time of Update: 2022-01-02
In the study of mice, they found evidence that the drug may also reduce some of the damage of the chemotherapy cocktail FOLFIRINOX (composed of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) commonly used to treat pancreatic cancer Sexual side effects .
-
The GMR 2021 2nd Intestinal Microecology and Disease Research and Transformation Forum was successfully held!
Time of Update: 2022-01-02
Twenty-seven domestic well-known academicians in scientific research and clinical end, PIs of tertiary hospitals, as well as leading representative companies in industrial transformation, and nearly 300 professional listeners gathered to open up a new future for intestinal micro-ecological diagnosis and treatment!This forum was co-sponsored by Shanghai Shangtu Information Consulting Co.
-
Microchip's overseas partner, Huya Biotechnology, announces that chidamine monotherapy has been approved in Japan for the treatment of peripheral T-cell lymphoma
Time of Update: 2022-01-02
S. HUYABIO INTERNATIONAL (hereinafter referred to as "HUYABIO International") text notice that it has obtained the patent of Microchip Technology to develop a new molecular entity, the world's first oral, subtype selective histone deacetylation Chidamide (HDAC) inhibitor Chidamide (generic name: Tucidinostat; Japanese trade name: Hiyast®; overseas code: HBI-8000) monotherapy for peripheral T-cell lymphoma (PTCL) indication approved by Japan Drug Administration Approved by the Bureau .
-
The new high-fidelity CRISPR Cas9 protein reduces off-target effects and enables more precise genome editing
Time of Update: 2022-01-02
For research applications that require highly precise genome editing, including engineering CAR-T cells and creating cell models for disease discovery, Invitrogen TrueCut HiFi Cas9 Protein* significantly reduces off-target events while maintaining maximum targeted editing efficiency .
-
Walk into the world of Agilent microplates (a free trial is available)
Time of Update: 2022-01-02
Agilent-MicroplateAgilent has rich professional experience in the design and manufacture of microplates, providing a wide range of standard microplates, using advanced technology to greatly improve the sample throughput and parallel processing efficiency of the reaction, and Agilent microplates comply with ANSI/SLAS Standards and strict Agilent quality control standards, and compatible with a variety of automated liquid handling equipment, is a microplate suitable for all workflows .
-
Genting Sunshine and Providence Therapeutics jointly announced a vaccine development strategy against the Omicron (B.1.1.529) variant of the new coronavirus
Time of Update: 2022-01-02
62em; font-family:"Arial"; color:black; margin:0in; } </> Shanghai, China and Calgary , Canada , December 1, 2021/PRNewswire/ --- Today, Genting Sunshine and Providence Therapeutics (hereinafter referred to as "Providence") jointly announced that they have begun to develop specifically for the new crown virus Omi Keron ( Omicron) COVID-19 vaccine against variant strains .
-
Implantable left ventricular assist system equipment approved for marketing
Time of Update: 2022-01-02
(Yan Ruoyu) Recently, a message published on the website of the State Food and Drug Administration showed that the registration application for the implantable left ventricular assist system, an innovative product produced by Suzhou Tongxin Medical Devices Co.
-
Diabetes drugs may revolutionize the treatment of heart failure
Time of Update: 2022-01-02
Early research suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors can help about half of patients with heart failure—those with reduced ejection fraction .
"For many years, there has not been a single drug that can improve the results of patients with type 2 heart failure-those with preserved ejection fraction .
-
Innovent and Ascent Pharmaceuticals jointly announced that China's first third-generation BCR-ABL inhibitor, Nerlik, has been approved for the treatment of chronic myeloid leukemia
Time of Update: 2022-01-02
pharmaceutical companies, today announced that the original class of drugs Ao Leiba erlotinib tablets (Olverembatinib, trade name: resistant gram ® ) formally approved by China's State Drug Administration (NMPA) approved for the treatment of any tyrosine kinase inhibitors Drug resistance (TKI), and the use of fully validated detection methods to diagnose chronic phase (CP) or accelerated phase (AP) adult chronic myeloid leukemia (CML) patients with T315I mutation .
-
NRG Oncology Non-Small Cell Lung Cancer Trial has completed Phase 2 and data analysis is in progress to determine the restart of Phase 3
Time of Update: 2022-01-02
If the trial restarts, the question of the third phase of the study will examine whether adding LCT to maintenance system therapy can improve the overall survival of patients with limited metastatic NSCLC .
-
my country's self-developed dual-carrier 13-valent pneumonia vaccine launched
Time of Update: 2022-01-01
Guangdong Provincial Maternal and Child Health Hospital pediatric emergency department director Zhao Changan said, as children vaccinated pneumonia vaccine is the best protection of children from harm is .
-
Thermo Fisher launches a new NGS kit for myeloid hematological tumors
Time of Update: 2022-01-01
Thermo Fisher launches Oncomine Myeloid Assay GX v2, which provides you with an extraordinary experience of obtaining a complete myeloid mutation map and analysis results in one day!One sample, one test can analyze all key mutationsOncomine Myeloid Assay GX v2 only requires a very low sample starting volume (10-20ng), which can simultaneously detect 45 DNA targets and 30 fusion driver genes .
-
Chaintech Biotech undertakes the construction of the official database of the International Human Proteome Project
Time of Update: 2022-01-01
62em; font-family:"Arial"; color:black; margin:0in; } </>Shenzhen, December 3, 2021/PRNewswire/ - Recently, the International Human Proteome Project confirmed that Chaintech Biotech will undertake the construction of the official database neXtProt (Asia sub-station) of the International Human Proteome Project .
-
People with bowel cancer have a high risk of depression
Time of Update: 2022-01-01
The research team is currently conducting another study on the impact of COVID-19, which is also funded by the Macmillan Cancer Support Center; the interim results found that four-fifths (81%) of cancer patients under investigation have been Staying at home, nearly half of them (45%) experienced at least two serious psychological effects of the pandemic, such as feeling scared, depressed, or helpless .
